


Sarilumab vs. Tocilizumab


Vague

48%




Skeptical

56%




Optimistic for Sarilumab (REMAP-CAP)

91%



Optimistic for Tocilizumab (inverse REMAP-CAP)

72%



← Favours Sarilumab Favours Tocilizumab →